This application is related to systems and methods of selecting, designing and manufacturing intraocular lenses that improve post-surgical spectacle independence in cataract patients.
Retinal image quality of intraocular lenses when implanted in the eye of a patient can be estimated from different metrics obtained from pre-clinical measurements. For example, through focus visual acuity for psuedophakic patients can be predicted from metrics based on various pre-clinical measurements. However, many of the metrics used to predict post-surgical optical performance of intraocular lenses are unable to reliably predict spectacle independence for psuedophakic patients. Spectacle independence is a desired outcome following cataract surgery for most patients. Accordingly, it would be desirable to develop new techniques to reliably predict the spectacle independence for pseudophakic patients receiving different IOLs.
This application contemplates systems and methods of predicting spectacle independence utilizing pre-clinical data to simulate and predict the expected percentage of patients that will be spectacle independent following cataract surgery with an IOL in which pre-clinical (measured or simulated) data is available. One piece of pre-clinical data that can be used to predict spectacle independence is through-focus visual acuity at one or more defocus positions. For example, it may be possible to predict spectacle independence based on through-focus visual acuity at near distances, such as, for example, near distances greater than or equal to about 25 cm and less than or equal to about 50 cm. However, there is limited information on whether a high peak in through-focus visual acuity at one near distance (e.g., 40 cm) is a better predictor of spectacle independence or whether a flat but lower through-focus visual acuity at a plurality of near distance values between about 25 cm and about 50 cm is a better predictor of spectacle independence. The methods and systems contemplated in this application are based on applying Bayesian models to an initial data set including known spectacle independence information obtained from clinical studies gathering responses to questions in a questionnaire from different patients implanted with different intraocular lenses for which measured or simulated pre-clinical data is available and calculating the probability that a patient would be spectacle independent for a certain value of visual acuity at a certain defocus distance. Since the initial data set is based on a small number of patients (e.g., less than or equal to about 500, less than or equal to about 1000, or less than or equal to about 2000), the prediction of spectacle independence from through-focus visual acuity values at one or more defocus positions can be calculated using “medium data” solutions that operate on medium sized databases. Additionally, machine learning can be employed to appropriately weight and scale the contribution of through-focus visual acuity performance at various defocus distances to spectacle independence.
One innovative aspect of the subject matter disclosed herein is implemented in an optical system configured to select an intraocular lens (IOL) from a plurality of IOLs for manufacture or for implantation into a patient eye, the selected IOL configured or to be manufactured to improve post-surgical spectacle independence outcome for the patient. The optical system comprises a processor configured to execute programmable instructions stored in a non-transitory computer storage medium; and a population database comprising clinical data for a plurality of patients less than or equal to about 5000 implanted with one of the plurality of IOLs, the clinical data comprising information related to spectacle independence for a plurality of values of visual acuity between about −0.2 log MAR and about 1 log MAR at various defocus conditions between about −5 D and 0 D, wherein the information related to spectacle independence is based on responses of the patients implanted with one of the plurality of IOLs to a questionnaire. The processor is configured to calculate for each of the plurality of IOLs, a probability of being spectacle independent for visual acuity equal to a threshold value between about −0.2 log MAR and about 1 log MAR at at least one defocus conditions between about −5 D and 0 D based on the information related to spectacle independence obtained from the population database; and identify one of the plurality of IOLs having a higher probability of being spectacle independent for manufacture or for implantation into the patient's eye.
The processor can be further configured to calculate for each of the plurality of IOLs, a probability of being spectacle independent for visual acuity equal to a threshold value between about −0.2 log MAR and about 1 log MAR at at least two or more defocus conditions between about −5 D and 0 D. The processor can be further configured to assign a weight to the probability of being spectacle independent for visual acuity equal to a threshold value between about −0.2 log MAR and about 1 log MAR at at least two or more defocus conditions between about −5 D and 0 D. The processor can be configured to execute a machine learning algorithm to determine the weight.
Another innovative aspect of the subject matter disclosed herein can be embodied in an optical system configured to identify an intraocular lens (IOL) that will improve post-surgical spectacle independence. The system comprises a processor configured to execute programmable instructions stored in a non-transitory computer storage medium to calculate a probability of achieving spectacle independence for at least two IOLs based on clinical data providing visual acuity at a first defocus position for the at least two IOLs in a population of patients implanted with one of the at least two IOLs; and identify one of the at least two IOLs having higher probability of achieving spectacle independence.
The processor can be further configured to calculate the probability of achieving spectacle independence for at least two IOLs based on at least one of: clinical data providing visual acuity at a second defocus position for the at least two IOLs in the population; standard deviation of pre-clinical visual acuity for the at least two IOLs at the first or the second defocus positions; clinical data providing minimum readable print size in mm in the population; modulation transfer function (MTF) at one or more frequencies at different distances for different pupil sizes; or area under the modulation transfer function at one or more frequencies at different distances for different pupil sizes.
The first defocus position can be about −2.5 D corresponding to a distance of about 40 cm. The second defocus position can have a value between about −5 D and about −0.5 D. A size of the population can be less than about 1000. The processor can be configured to execute programmable instructions stored in a non-transitory computer storage medium to transmit one or more parameters of the identified IOL to a display device or an IOL manufacturing system.
Yet another innovative aspect of the subject matter disclosed herein is implemented in a system for predicting post-surgical spectacle independence of one or more IOLs, the system comprising a processor configured to execute programmable instructions stored in a non-transitory computer storage medium to calculate a probability of achieving spectacle independence for the one or more IOLs based on clinical data providing visual acuity at one or more defocus position for the one or more IOLs in a population of patients implanted with one of the one or more IOLs.
The processor can be further configured to execute programmable instructions stored in a non-transitory computer storage medium to calculate the probability of achieving spectacle independent based on one or more combinations of visual acuity at at least two or more defocus positions for the one or more IOLs in the population. The processor can be further configured to execute programmable instructions stored in a non-transitory computer storage medium to assign weights to the one or more combinations of visual acuity. The weights can be determined based on a machine learning algorithm.
An innovative aspect of the subject matter disclosed herein is implemented in a method of manufacturing an IOL comprising: receiving one or more parameters of an IOL selected from a plurality of IOLs based on calculating a probability of achieving spectacle independence for the plurality of IOLs from clinical data providing visual acuity at one or more defocus position for the plurality of IOLs in a population of patients implanted with one of the plurality of IOLs; and manufacturing the selected IOL.
Embodiments of the present invention may be better understood from the following detailed description when read in conjunction with the accompanying drawings. Such embodiments, which are for illustrative purposes only, depict novel and non-obvious aspects of the invention. The drawings include the following figures:
Each and every feature described herein, and each and every combination of two or more of such features, is included within the scope of the present invention provided that the features included in such a combination are not mutually inconsistent.
As used herein, the terms “about” or “approximately”, when used in reference to a Diopter value of an optical power, mean within plus or minus 0.25 Diopter of the referenced optical power(s). As used herein, the terms “about” or “approximately”, when used in reference to a percentage (%), mean within plus or minus one percent (±1%). As used herein, the terms “about” or “approximately”, when used in reference to a linear dimension (e.g., length, width, thickness, distance, etc.) mean within plus or minus one percent (1%) of the value of the referenced linear dimension.
Spectacle independence is a highly desired outcome following cataract surgery. It is possible to predict through-focus visual acuity (VA) for different implementations of intraocular lenses (IOLs) based on pre-clinical data using mathematical models. Through-focus VA can be predicted for one or more defocus values based on available pre-clinical data for an IOL including but not limited to IOL characteristics such as refractive index of the IOL, radii of curvature, diffraction power, diffraction step height, transition zones and IOL thickness. These characteristics can be used in a ray tracing simulation software to predict through-focus MTF, which can predict through-focus VA. IOL designs can be optimized to achieve a desired optical performance based on the predicted values of through-focus VA.
The predicted through-focus VA at one or more defocus values can be based on an output generated by an electronic processor from available pre-clinical data of the IOL input to the electronic processor. The electronic processor can be configured to execute instructions stored on a non-transitory hardware storage medium to generate the output. An example electronic processing system is discussed in detail below with reference to
This application contemplates systems and methods to predict the expected percentage of patients that will be spectacle independent based when implanted with an IOL whose pre-clinical data is available. The spectacle independence can be estimated using Bayesian analysis. Bayesian analysis is a statistical procedure which combines prior distribution of one or more population parameters before any data is observed with observed information in a sample to obtain an updated probability distribution for the one or more parameters.
When using Bayes analysis to estimate spectacle independence from pre-clinical data, A can correspond to the pdf of different percentages of spectacle independence, and B can correspond to the clinical data that is used to predict spectacle independence.
The clinical data can be a singular value or a multidimensional value. Through-focus VA is an example of a multidimensional value (for example, VA at −3 D, at −2.5 D, at −2 D, . . . , at 0 D of defocus). A singular value can also be used to predict the percentage of spectacle independence. Predicting spectacle independence based on a singular value can be simple and computationally less intensive. Singular values used for predicting spectacle independence can include (i) VA at near distance (e.g., 40 cm), (ii) VA at any other distance, (iii) standard deviation of VA in a certain distance/defocus range which can be a measure of the variability/consistency of VA in the distance/defocus range, (iv) minimum readable print size in mm calculated by predicted angular VA which is converted to stroke width of letters in mm at that distance and taking the minimum value. This corresponds to best distance at which a patient can view small print, (v) modulation transfer function (MTF) at certain spatial frequencies at certain distances and pupil sizes, or (vi) Area under MTF curve at certain distances and pupil sizes.
For singular value metrics B, A can comprise a plurality of probabilities i of spectacle independence, such as 1%, 2%, 3%, . . . , 99%, 100%. The conditional probability of P(A_i|B) can be calculated using Bayes' rule by the equation
The plurality of probabilities of different percentages of spectacle independence P(A_i) can be determined based on a prior model of spectacle independence, such as having a linear function between 5% and 95%, in the VA range from 0.6 Log MAR to 0 Log MAR at a certain defocus value (e.g., −2.5 D). Bayes analysis can then be used to estimate the probability P(B|A_i), the probability of the set given clinical data assuming spectacle independence A_i through direct calculation from the clinical data as well as the model. P(B) can be considered as a normalization factor.
The method discussed above can be applied for multidimensional values as well. However, some modification and additional techniques may be required when the multidimensional value metric is through-focus VA at different defocus values, since VA at different defocus values may be correlated. Due to the relatively large number of defocus positions, correcting for interaction effects may not possible. In some implementations of Bayesian analysis that employs through-focus VA at different defocus values as the pre-clinical metric, a multidimensional matrix including all possible combinations of VA values at different defocus values may be generated. This matrix can be sampled, for example, in steps of 0.5 D and 0.1 Log MAR. At each such combination there is a pdf for different percentages of spectacle independence. The data added into the matrix could be additive for any VA at any value higher than the given curve for, thus phrasing the probabilities as “having VA of x or higher”.
This method is illustrated in
which is equal to 75%.
Another example to illustrate the method of determining spectacle independence based on visual acuity is described below. For the sake of simplicity a singular value metric is used to estimate spectacle independence, but the same techniques can be generalized when a multidimensional value is used.
Consider that it is desired to investigate the probability of being spectacle independent if VA at −2.5 D is −0.05 Log MAR. From a clinical data set obtained from observation of 321 subjects, it is found that there are four subjects who are not spectacle independent and have VA at −2.5 D greater than or equal to −0.05 and there are 16 subjects who are spectacle independent and have VA at −2.5 D greater than or equal to −0.05. From the clinical data set, it is further observed that there are 155 subjects who are not spectacle independent and have VA at −2.5 D less than −0.05 and 146 subjects who are spectacle independent and have VA at −2.5 D less than −0.05.
Based on the information, the probability of being spectacle independent when VA at −2.5 D is greater than or equal to −0.05 P(SI|VA at −2.5 D>−0.05)=P(VA at −2.5 D>−0.05|SI)*P(SI)/P(VA at −2.5 D>−0.05) which is equal to (16/162)*(162/321)/(20/321) which is equal to 80%.
It is further noted from
Using Bayes analysis, the probability of being spectacle dependent and having a VA of 0.3 Log MAR or worse P(SD|VA of 0.3 Log MAR or worse)=P(VA of 0.3 Log MAR or worse|SD)*P(SD)/P(VA of 0.3 Log MAR or worse) which is equal to (102/158)*(158/315)/(115/315)=88.7%. Thus, there is an 11.3% chance of being spectacle independent if the VA is 0.3 Log MAR or worse. Thus, the model of predicting spectacle independence based on singular VA value can be updated by combining the two estimates to better predict the chance of being spectacle independent given a certain VA value as described below.
Consider a vector t of length 100 with the probabilities of having 1%, 2%, 3% . . . , 99%, 100% spectacle independent at a certain value of VA. The vector t can be updated according to the example below.
Consider that the vector t has a length of 2 with a 0.5 probability of 80% being spectacle independent and 0.5 probability of 70% being spectacle independent. For VA values above −0.05 we have 4 subjects who wear spectacles and 16 subjects who don't wear spectacles. The probability of being spectacle independent for VA above −0.05, can be calculated using the P(x)=(N!/(x! (N−x)!))*(fx)*(l−t){circumflex over ( )}(N−x) where N is total number, x is the number of spectacle independent and t is the probability. For the example above, N=20, x=16 and t=0.7 and 0.8. Accordingly, P(x) is equal to 0.13 for t=0.7 and 0.21 for t=0.8. If the initial prior pdf P(A) is [0.5, 0.5], and P(B) is applied as a standard normalization factor, P(A|B)=[0.5*0.13, 0.5*0.21]/(0.5*0.13+0.5*0.21)=0.38 for t=0.7, and 0.62 for t=0.8. In this manner the vector t is updated. A similar technique can be applied for estimating spectacle independence for VA worse than a certain value, and the results combined using a range of methods. A skilled person would understand that it is advantageous to start with a reasonable prior pdf as the posterior probability distribution can skew towards the prior pdf when the number of subjects is low.
The abovementioned technique can also be applied to the multidimensional case, where a larger matrix is used and a combination of VA applicable to all defocus positions is selected. In such a case, the sampling may be limited. The sampling limitation can be overcome by using a two-step process, wherein first a coarse sampling is applied, e.g. steps of 0.1 Log MAR. Thereafter, if the VA of interest to test is e.g. 0.12, we combine the two nearby steps, with 80% weight to estimates for VA=0.1 and 20% weight to the estimate with VA=0.2.
The Bayesian analysis method can be expanded to cover more than a binary outcome of spectacle dependent/spectacle independent, and instead describe the probability of never wearing spectacles, of wearing spectacles a little bit of the time, some of the time, or all of the time.
The Bayesian analysis method can be expanded to incorporate other characteristics of the patients, such as age, gender, eye length, pupil size, ethnicity, corneal aberrations, life style or combinations thereof.
The Bayesian analysis method of estimating spectacle independence for different parameters can be incorporated in an IOL design and/or manufacturing process. The parameter space of IOL design allows variation of IOL characteristics such as radii of curvature, diffraction power, diffraction step height, transition zones and IOL thickness. These characteristics can be used in a ray tracing simulation software to predict through focus MTF, which can predict VA. Using Bayesian analysis, the probability of spectacle independence can be calculated, and the IOL characteristics optimized such that the highest possible spectacle independence is achieved, in conjunction with other simulated and desired constraints such as distance image quality. Bayesian analysis can also be used to predict how suitable certain treatment techniques, such as making the patients slightly myopic postoperatively can positively affect spectacle independence. Bayesian analysis to estimate spectacle independence can also be used to select an IOL for implantation in a patient that would increase the chance of the patient to be spectacle independent for a variety of tasks such as reading, viewing a smartphone, computer use or combinations thereof.
The spectacle independence of five different implementations of IOLs was predicted based on pre-clinical data based on the Bayesian analysis method described above. To predict spectacle independence, a data set of 321 patients from three different studies was used. The patients were bilaterally implanted with five different implementations of IOLs. Spectacle independence was coded as a binary outcome. Through focus VA was varied in steps of 0.5 D between −3 D and 0 D. A Bayesian model to estimate rate of spectacle independence was developed. The Bayesian model was configured to calculate probability of spectacle independence for VA better than a certain value as well as probability of spectacle dependence for VA worse than a certain value. The Bayesian model was further configured to calculate probability with different combinations of VA at different defocus values. For example, the Bayesian model was configured to (i) calculate probability of VA greater than or worse than a certain value for different single defocus values (e.g., 0 D, −0.5 D, −1 D, −1.5 D, −2 D, −2.5 D, −3 D), (ii) calculate probability of VA greater than or worse than a certain value for combinations of two different defocus values (e.g., −3 D and −2.5 D, −2 D and −1 D), and (iii) calculate probability of VA greater than or worse than a certain value for combinations of three or more different defocus values. For example, the model was configured to calculate probability of VA greater than or worse than a certain value for combination of seven different defocus values (e.g., 0 D, −0.5 D, −1 D, −1.5 D, −2 D, −2.5 D, and −3 D).
The model was trained to combine and weight the different probabilities in order to have outcomes closest to the reported rates of spectacle independence. For example, probability of VA greater than or worse than a certain value for combination of two or more different defocus values that are closer to each other was assigned a higher weight than probability of VA greater than or worse than a certain value for combination of two or more different defocus values that are farther from each other. As another example, probability of VA greater than or worse than a certain value for different defocus values corresponding to near distances between 25 cm and about 40 cm can be assigned a higher weight than VA at other defocus values.
The table below shows the clinically measured percentage spectacle independence for five different IOL implementations Lens 1, Lens 2, Lens 3, Lens 4 and Lens 5. The predicted percentage of spectacle independence using a Bayesian model with multidimensional values as described herein as well as a single through-focus VA at one defocus value is also shown in the table below. The average error and the r{circumflex over ( )}2 values for the different Bayesian models are also included in the table below.
It is noted from the table above that the Bayesian model based on through-focus VA at a plurality of defocus values as described herein had the highest degree of correlation (r{circumflex over ( )}2 of 0.96 with the clinically measured spectacle independence.
The benefit of inducing 0.5 D of myopia for mini-monovision can also be evaluated using the through focus VA predicted from pre-clinical methods.
Referring to
The array of ordered values 608 may comprise, for example, one or more ocular dimensions of an eye or plurality of eyes from a database, a desired refractive outcome, parameters of an eye model based on one or more characteristics of at least one eye, and data related to an IOL or set of IOLs such as a power, clinical data providing the number of subjects who are spectacle dependent at one or more VA values, and/or clinical data providing the number of subjects who are spectacle independent at one or more VA values. In some embodiments, the sequence of instructions 610 includes variation of IOL characteristics such as radii of curvature, diffraction power, diffraction step height, transition zones and IOL thickness, using these characteristics in a ray tracing simulation software to predict through-focus VA, using Bayesian analysis to predict the probability of spectacle independence, optimize IOL characteristics to increase spectacle independence or select an IOL having the highest probability of spectacle independence.
The computer system 600 may be a general purpose desktop or laptop computer or may comprise hardware specifically configured performing the desired calculations. In some embodiments, the computer system 600 is configured to be electronically coupled to another device such as a phacoemulsification console or one or more instruments for obtaining measurements of an eye or a plurality of eyes. In other embodiments, the computer system 600 is a handheld device that may be adapted to be electronically coupled to one of the devices just listed. In yet other embodiments, the computer system 600 is, or is part of, refractive planner configured to provide one or more suitable intraocular lenses for implantation based on physical, structural, and/or geometric characteristics of an eye, and based on other characteristics of a patient or patient history, such as the age of a patient, medical history, history of ocular procedures, life preferences, and the like.
In certain embodiments, the system 600 includes or is part a phacoemulsification system, laser treatment system, optical diagnostic instrument (e.g, autorefractor, aberrometer, and/or corneal topographer, or the like). For example, the computer readable memory 604 may additionally contain instructions for controlling the handpiece of a phacoemulsification system or similar surgical system. Additionally or alternatively, the computer readable memory 604 may additionally contain instructions for controlling or exchanging data with an autorefractor, aberrometer, tomographer, and/or topographer, or the like.
Rates of spectacle independence can be predicted from through focus VA. It is better to use a combination of VA at many distances than any one distance. Models based on combining clinical data from many studies can offer greater understanding of potential patient outcomes, such as predicting benefits from mini-monovision using EDOF IOLs.
The above presents a description of the best mode contemplated of carrying out the concepts disclosed herein, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains to make and use the concepts described herein. The systems, methods and devices disclosed herein are, however, susceptible to modifications and alternate constructions from that discussed above which are fully equivalent. Consequently, it is not the intention to limit the scope of this disclosure to the particular embodiments disclosed. On the contrary, the intention is to cover modifications and alternate constructions coming within the spirit and scope of the present disclosure as generally expressed by the following claims, which particularly point out and distinctly claim the subject matter of the implementations described herein.
Although embodiments have been described and pictured in an example form with a certain degree of particularity, it should be understood that the present disclosure has been made by way of example, and that numerous changes in the details of construction and combination and arrangement of parts and steps may be made without departing from the spirit and scope of the disclosure as set forth in the claims hereinafter.
As used herein, the term “processor” refers broadly to any suitable device, logical block, module, circuit, or combination of elements for executing instructions. For example, the processor 1002 can include any conventional general purpose single- or multi-chip microprocessor such as a Pentium® processor, a MIPS® processor, a Power PC® processor, AMD® processor, ARM processor, or an ALPHA® processor. In addition, the processor 602 can include any conventional special purpose microprocessor such as a digital signal processor. The various illustrative logical blocks, modules, and circuits described in connection with the embodiments disclosed herein can be implemented or performed with a general purpose processor, a digital signal processor (DSP), an application specific integrated circuit (ASIC), a field programmable gate array (FPGA), or other programmable logic device, discrete gate or transistor logic, discrete hardware components, or any combination thereof designed to perform the functions described herein. Processor 302 can be implemented as a combination of computing devices, e.g., a combination of a DSP and a microprocessor, a plurality of microprocessors, one or more microprocessors in conjunction with a DSP core, or any other such configuration.
Computer readable memory 604 can refer to electronic circuitry that allows information, typically computer or digital data, to be stored and retrieved. Computer readable memory 604 can refer to external devices or systems, for example, disk drives or solid state drives. Computer readable memory 1004 can also refer to fast semiconductor storage (chips), for example, Random Access Memory (RAM) or various forms of Read Only Memory (ROM), which are directly connected to the communication bus or the processor 602. Other types of memory include bubble memory and core memory. Computer readable memory 604 can be physical hardware configured to store information in a non-transitory medium.
Methods and processes described herein may be embodied in, and partially or fully automated via, software code modules executed by one or more general and/or special purpose computers. The word “module” can refer to logic embodied in hardware and/or firmware, or to a collection of software instructions, possibly having entry and exit points, written in a programming language, such as, for example, C or C++. A software module may be compiled and linked into an executable program, installed in a dynamically linked library, or may be written in an interpreted programming language such as, for example, BASIC, Perl, or Python. It will be appreciated that software modules may be callable from other modules or from themselves, and/or may be invoked in response to detected events or interrupts. Software instructions may be embedded in firmware, such as an erasable programmable read-only memory (EPROM). It will be further appreciated that hardware modules may comprise connected logic units, such as gates and flip-flops, and/or may comprised programmable units, such as programmable gate arrays, application specific integrated circuits, and/or processors. The modules described herein can be implemented as software modules, but also may be represented in hardware and/or firmware. Moreover, although in some embodiments a module may be separately compiled, in other embodiments a module may represent a subset of instructions of a separately compiled program, and may not have an interface available to other logical program units.
In certain embodiments, code modules may be implemented and/or stored in any type of computer-readable medium or other computer storage device. In some systems, data (and/or metadata) input to the system, data generated by the system, and/or data used by the system can be stored in any type of computer data repository, such as a relational database and/or flat file system. Any of the systems, methods, and processes described herein may include an interface configured to permit interaction with users, operators, other systems, components, programs, and so forth.
This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Patent Application No. 62/593,162, filed Nov. 30, 2017, which is incorporated herein by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2077092 | Broder | Apr 1937 | A |
3305294 | Alvarez | Feb 1967 | A |
3367734 | Karl | Feb 1968 | A |
3735685 | Plummer | May 1973 | A |
4010496 | Neefe | Mar 1977 | A |
4056311 | Winthrop | Nov 1977 | A |
4077071 | Freeman | Mar 1978 | A |
4093361 | Erickson et al. | Jun 1978 | A |
4134160 | Bayers | Jan 1979 | A |
4162122 | Cohen | Jul 1979 | A |
4174543 | Kelman | Nov 1979 | A |
4210391 | Cohen et al. | Jul 1980 | A |
4249272 | Poler | Feb 1981 | A |
4254509 | Tennant | Mar 1981 | A |
4254510 | Tennant | Mar 1981 | A |
4316293 | Bayers | Feb 1982 | A |
4319564 | Karickhoff | Mar 1982 | A |
4338005 | Cohen | Jul 1982 | A |
4340283 | Cohen | Jul 1982 | A |
4370760 | Kelman | Feb 1983 | A |
4377873 | Reichert, Jr. | Mar 1983 | A |
4402579 | Poler | Sep 1983 | A |
4403353 | Tennant | Sep 1983 | A |
4404694 | Kelman | Sep 1983 | A |
4409691 | Levy | Oct 1983 | A |
4424597 | Schlegel | Jan 1984 | A |
4437733 | Takahashi et al. | Mar 1984 | A |
4446581 | Blake | May 1984 | A |
4480340 | Shepard | Nov 1984 | A |
4500382 | Foster | Feb 1985 | A |
4504982 | Burk | Mar 1985 | A |
4551864 | Akhavi | Nov 1985 | A |
4556998 | Siepser | Dec 1985 | A |
4560383 | Leiske | Dec 1985 | A |
4605409 | Kelman | Aug 1986 | A |
4605411 | Fedorov et al. | Aug 1986 | A |
4629460 | Dyer | Dec 1986 | A |
4629462 | Feaster | Dec 1986 | A |
4637697 | Freeman | Jan 1987 | A |
4642112 | Freeman | Feb 1987 | A |
4655565 | Freeman | Apr 1987 | A |
4665913 | L'Esperance, Jr. | May 1987 | A |
4669466 | L'Esperance | Jun 1987 | A |
4673406 | Schlegel | Jun 1987 | A |
4676791 | Lemaster et al. | Jun 1987 | A |
4676792 | Praeger | Jun 1987 | A |
4681102 | Bartell | Jul 1987 | A |
4687484 | Kaplan | Aug 1987 | A |
4687485 | Lim et al. | Aug 1987 | A |
RE32525 | Pannu | Oct 1987 | E |
4725277 | Bissonette | Feb 1988 | A |
4732148 | L'Esperance, Jr. | Mar 1988 | A |
4734095 | Siepser | Mar 1988 | A |
4764930 | Bille et al. | Aug 1988 | A |
4770172 | L'Esperance, Jr. | Sep 1988 | A |
4773414 | L'Esperance, Jr. | Sep 1988 | A |
4778462 | Grendahl | Oct 1988 | A |
4781717 | Grendahl | Nov 1988 | A |
4787903 | Grendahl | Nov 1988 | A |
4787904 | Severin et al. | Nov 1988 | A |
4795462 | Grendahl | Jan 1989 | A |
4798608 | Grendahl | Jan 1989 | A |
4798609 | Grendahl | Jan 1989 | A |
4828558 | Kelman | May 1989 | A |
4834748 | McDonald | May 1989 | A |
4863261 | Flammer | Sep 1989 | A |
4863539 | Lee et al. | Sep 1989 | A |
4898461 | Portney | Feb 1990 | A |
4932970 | Portney | Jun 1990 | A |
4995714 | Cohen | Feb 1991 | A |
4995715 | Cohen | Feb 1991 | A |
4997442 | Barrett | Mar 1991 | A |
5016977 | Baude et al. | May 1991 | A |
5019097 | Knight et al. | May 1991 | A |
5042938 | Shimozono | Aug 1991 | A |
5047052 | Dubroff | Sep 1991 | A |
5054905 | Cohen | Oct 1991 | A |
5056908 | Cohen | Oct 1991 | A |
5066301 | Wiley | Nov 1991 | A |
5071432 | Baikoff | Dec 1991 | A |
5078742 | Dahan | Jan 1992 | A |
5089023 | Swanson | Feb 1992 | A |
5096285 | Silberman | Mar 1992 | A |
5108388 | Trokel et al. | Apr 1992 | A |
5114220 | Baude et al. | May 1992 | A |
5117306 | Cohen | May 1992 | A |
5120120 | Cohen | Jun 1992 | A |
5121979 | Cohen | Jun 1992 | A |
5121980 | Cohen | Jun 1992 | A |
5133749 | Nordan | Jul 1992 | A |
5144483 | Cohen | Sep 1992 | A |
5147395 | Willis | Sep 1992 | A |
5147397 | Christ et al. | Sep 1992 | A |
5163934 | Munnerlyn | Nov 1992 | A |
5173723 | Volk et al. | Dec 1992 | A |
5184405 | Cress | Feb 1993 | A |
5197981 | Southard | Mar 1993 | A |
5201763 | Brady et al. | Apr 1993 | A |
5203790 | McDonald | Apr 1993 | A |
5207668 | L'Esperance, Jr. | May 1993 | A |
5217491 | Vanderbilt | Jun 1993 | A |
5219343 | L'Esperance, Jr. | Jun 1993 | A |
5225858 | Portney | Jul 1993 | A |
5229797 | Futhey et al. | Jul 1993 | A |
5258025 | Fedorov et al. | Nov 1993 | A |
5278592 | Marie et al. | Jan 1994 | A |
5379110 | Matsui et al. | Jan 1995 | A |
5408281 | Zhang | Apr 1995 | A |
5433745 | Graham et al. | Jul 1995 | A |
5476513 | Brady et al. | Dec 1995 | A |
5479220 | Komatsu et al. | Dec 1995 | A |
5567365 | Weinschenk, III et al. | Oct 1996 | A |
5571177 | Deacon et al. | Nov 1996 | A |
5620720 | Glick et al. | Apr 1997 | A |
5628796 | Suzuki | May 1997 | A |
5646791 | Glockler | Jul 1997 | A |
5652638 | Roffman et al. | Jul 1997 | A |
5652640 | Schneider et al. | Jul 1997 | A |
5691800 | Iki et al. | Nov 1997 | A |
5699142 | Lee et al. | Dec 1997 | A |
5716403 | Tran et al. | Feb 1998 | A |
5748282 | Freeman | May 1998 | A |
5760871 | Kosoburd et al. | Jun 1998 | A |
5796462 | Roffman et al. | Aug 1998 | A |
5801807 | Satake et al. | Sep 1998 | A |
5928282 | Nigam | Jul 1999 | A |
5968094 | Werblin et al. | Oct 1999 | A |
5993438 | Juhasz et al. | Nov 1999 | A |
6015435 | Valunin et al. | Jan 2000 | A |
6051024 | Cumming | Apr 2000 | A |
6126283 | Wen et al. | Oct 2000 | A |
6126286 | Portney | Oct 2000 | A |
6129759 | Chambers | Oct 2000 | A |
6142625 | Sawano et al. | Nov 2000 | A |
6179870 | Sourdille et al. | Jan 2001 | B1 |
6210005 | Portney | Apr 2001 | B1 |
6235055 | Chu | May 2001 | B1 |
6241356 | Von Wallfeld et al. | Jun 2001 | B1 |
6261321 | Kellan | Jul 2001 | B1 |
6319282 | Nishi | Nov 2001 | B1 |
6338559 | Williams et al. | Jan 2002 | B1 |
6419697 | Kelman | Jul 2002 | B1 |
6457826 | Lett | Oct 2002 | B1 |
6460997 | Frey et al. | Oct 2002 | B1 |
6464355 | Gil | Oct 2002 | B1 |
6474814 | Griffin | Nov 2002 | B1 |
6488708 | Sarfarazi | Dec 2002 | B2 |
6491721 | Freeman et al. | Dec 2002 | B2 |
6497483 | Frey et al. | Dec 2002 | B2 |
6527389 | Portney | Mar 2003 | B2 |
6533416 | Fermigier et al. | Mar 2003 | B1 |
6536899 | Fiala | Mar 2003 | B1 |
6537317 | Steinert et al. | Mar 2003 | B1 |
6547822 | Lang | Apr 2003 | B1 |
6550917 | Neal et al. | Apr 2003 | B1 |
6554859 | Lang et al. | Apr 2003 | B1 |
6557992 | Dwyer et al. | May 2003 | B1 |
6575572 | Lai et al. | Jun 2003 | B2 |
6598606 | Terwee et al. | Jul 2003 | B2 |
6609793 | Norrby et al. | Aug 2003 | B2 |
6705729 | Piers et al. | Mar 2004 | B2 |
6786603 | Altmann | Sep 2004 | B2 |
6802605 | Cox et al. | Oct 2004 | B2 |
6808262 | Chapoy et al. | Oct 2004 | B2 |
6817714 | Altmann | Nov 2004 | B2 |
6830332 | Piers et al. | Dec 2004 | B2 |
6846326 | Zadno-Azizi et al. | Jan 2005 | B2 |
6851803 | Wooley et al. | Feb 2005 | B2 |
6899425 | Roffman et al. | May 2005 | B2 |
6923539 | Simpson et al. | Aug 2005 | B2 |
6923540 | Ye et al. | Aug 2005 | B2 |
6986578 | Jones | Jan 2006 | B2 |
7036931 | Lindacher et al. | May 2006 | B2 |
7048760 | Cumming | May 2006 | B2 |
7061693 | Zalevsky | Jun 2006 | B2 |
7073906 | Portney | Jul 2006 | B1 |
7137702 | Piers et al. | Nov 2006 | B2 |
7156516 | Morris et al. | Jan 2007 | B2 |
7188949 | Bandhauer et al. | Mar 2007 | B2 |
7281797 | Yamaguchi et al. | Oct 2007 | B2 |
7287852 | Fiala | Oct 2007 | B2 |
7293873 | Dai et al. | Nov 2007 | B2 |
7296893 | Dai | Nov 2007 | B2 |
7339539 | Joannopoulos et al. | Mar 2008 | B2 |
7350916 | Hong et al. | Apr 2008 | B2 |
7365917 | Zalevsky | Apr 2008 | B2 |
7377640 | Piers et al. | May 2008 | B2 |
7425068 | Koest | Sep 2008 | B2 |
7441894 | Zhang et al. | Oct 2008 | B2 |
7455404 | Bandhauer et al. | Nov 2008 | B2 |
7455407 | Neal et al. | Nov 2008 | B2 |
7475986 | Dai et al. | Jan 2009 | B2 |
7547102 | Dai | Jun 2009 | B2 |
7615073 | Deacon et al. | Nov 2009 | B2 |
7616330 | Neal et al. | Nov 2009 | B2 |
7659971 | Warden et al. | Feb 2010 | B2 |
7726813 | Dai | Jun 2010 | B2 |
7784946 | Leblanc | Aug 2010 | B2 |
7794497 | Brady et al. | Sep 2010 | B2 |
7857451 | Thibos et al. | Dec 2010 | B2 |
7871162 | Weeber | Jan 2011 | B2 |
7911211 | Crain et al. | Mar 2011 | B2 |
7931371 | Dai | Apr 2011 | B2 |
7931374 | Dai et al. | Apr 2011 | B2 |
7938538 | Lu et al. | May 2011 | B2 |
7944553 | Simpson et al. | May 2011 | B1 |
7969585 | Neal et al. | Jun 2011 | B2 |
8123357 | Dai et al. | Feb 2012 | B2 |
8382281 | Weeber | Feb 2013 | B2 |
8480228 | Weeber | Jul 2013 | B2 |
8596787 | Dai | Dec 2013 | B2 |
8657445 | Olsen | Feb 2014 | B2 |
8696119 | Van Der Mooren et al. | Apr 2014 | B2 |
8740382 | Liu et al. | Jun 2014 | B1 |
8746882 | Vidal et al. | Jun 2014 | B2 |
8764822 | Harris et al. | Jul 2014 | B2 |
8862447 | Weeber | Oct 2014 | B2 |
9211061 | Kasthurirangan et al. | Dec 2015 | B2 |
9241627 | Steinmueller | Jan 2016 | B2 |
9393108 | Canovas Vidal et al. | Jul 2016 | B2 |
9491431 | Zhou | Nov 2016 | B2 |
9700201 | Bex et al. | Jul 2017 | B2 |
20010051825 | Peterson | Dec 2001 | A1 |
20020118337 | Perrott et al. | Aug 2002 | A1 |
20020173846 | Blake et al. | Nov 2002 | A1 |
20020196408 | Bhalakia et al. | Dec 2002 | A1 |
20020196412 | Abitbol | Dec 2002 | A1 |
20030033013 | Callahan et al. | Feb 2003 | A1 |
20030053025 | Turner et al. | Mar 2003 | A1 |
20030076478 | Cox | Apr 2003 | A1 |
20030163122 | Sumiya | Aug 2003 | A1 |
20030171808 | Phillips | Sep 2003 | A1 |
20030189690 | Mihashi et al. | Oct 2003 | A1 |
20040021824 | Ye et al. | Feb 2004 | A1 |
20040021825 | Richardson | Feb 2004 | A1 |
20040054358 | Cox et al. | Mar 2004 | A1 |
20040057010 | Altmann | Mar 2004 | A1 |
20040068317 | Knight | Apr 2004 | A1 |
20040085515 | Roffman et al. | May 2004 | A1 |
20040106992 | Lang et al. | Jun 2004 | A1 |
20040111153 | Woods et al. | Jun 2004 | A1 |
20040150789 | Jones | Aug 2004 | A1 |
20040156014 | Piers et al. | Aug 2004 | A1 |
20040167622 | Sunalp et al. | Aug 2004 | A1 |
20040183997 | Suzuki | Sep 2004 | A1 |
20040230299 | Simpson et al. | Nov 2004 | A1 |
20040260275 | Liang et al. | Dec 2004 | A1 |
20050024647 | Montgomery | Feb 2005 | A1 |
20050096226 | Stock et al. | May 2005 | A1 |
20050122474 | Koretz | Jun 2005 | A1 |
20050125056 | Deacon et al. | Jun 2005 | A1 |
20050128432 | Altmann | Jun 2005 | A1 |
20050195364 | Dai | Sep 2005 | A1 |
20050203619 | Altmann | Sep 2005 | A1 |
20050251254 | Brady et al. | Nov 2005 | A1 |
20050267575 | Nguyen et al. | Dec 2005 | A1 |
20060009816 | Fang et al. | Jan 2006 | A1 |
20060030938 | Altmann | Feb 2006 | A1 |
20060034003 | Zalevsky | Feb 2006 | A1 |
20060055877 | Yanari | Mar 2006 | A1 |
20060055883 | Morris et al. | Mar 2006 | A1 |
20060066808 | Blum et al. | Mar 2006 | A1 |
20060068453 | Altieri | Mar 2006 | A1 |
20060098162 | Bandhauer et al. | May 2006 | A1 |
20060098163 | Bandhauer et al. | May 2006 | A1 |
20060109421 | Ye et al. | May 2006 | A1 |
20060116763 | Simpson | Jun 2006 | A1 |
20060116764 | Simpson | Jun 2006 | A1 |
20060116765 | Blake et al. | Jun 2006 | A1 |
20060176572 | Fiala | Aug 2006 | A1 |
20060203198 | Liang | Sep 2006 | A1 |
20060238702 | Glick et al. | Oct 2006 | A1 |
20060244904 | Hong et al. | Nov 2006 | A1 |
20060244906 | Piers et al. | Nov 2006 | A1 |
20060244916 | Guillon | Nov 2006 | A1 |
20060274268 | Andino et al. | Dec 2006 | A1 |
20060279699 | Liang | Dec 2006 | A1 |
20060279700 | Liang | Dec 2006 | A1 |
20070052920 | Stewart et al. | Mar 2007 | A1 |
20070052927 | Noda et al. | Mar 2007 | A1 |
20070129803 | Cumming et al. | Jun 2007 | A1 |
20070171362 | Simpson et al. | Jul 2007 | A1 |
20070182924 | Hong et al. | Aug 2007 | A1 |
20070195265 | Dreher et al. | Aug 2007 | A1 |
20070211214 | Dai | Sep 2007 | A1 |
20070268453 | Hong et al. | Nov 2007 | A1 |
20070285617 | Mills et al. | Dec 2007 | A1 |
20080018910 | Neal et al. | Jan 2008 | A1 |
20080030677 | Simpson | Feb 2008 | A1 |
20080033546 | Liang | Feb 2008 | A1 |
20080079895 | Jubin et al. | Apr 2008 | A1 |
20080161913 | Brady et al. | Jul 2008 | A1 |
20080161914 | Brady et al. | Jul 2008 | A1 |
20080198331 | Azar et al. | Aug 2008 | A1 |
20080231809 | Haigis | Sep 2008 | A1 |
20080269642 | Deacon et al. | Oct 2008 | A1 |
20080273169 | Blum et al. | Nov 2008 | A1 |
20080291393 | Menezes | Nov 2008 | A1 |
20090000628 | Somani et al. | Jan 2009 | A1 |
20090012609 | Geraghty et al. | Jan 2009 | A1 |
20090036980 | Norrby et al. | Feb 2009 | A1 |
20090062911 | Bogaert | Mar 2009 | A1 |
20090164008 | Hong et al. | Jun 2009 | A1 |
20090168019 | Tuan | Jul 2009 | A1 |
20090187242 | Weeber et al. | Jul 2009 | A1 |
20090210054 | Weeber et al. | Aug 2009 | A1 |
20090231546 | Dai | Sep 2009 | A1 |
20090234448 | Weeber et al. | Sep 2009 | A1 |
20090268155 | Weeber | Oct 2009 | A1 |
20090268158 | Weeber | Oct 2009 | A1 |
20090275929 | Zickler | Nov 2009 | A1 |
20090279048 | Hong et al. | Nov 2009 | A1 |
20090281552 | Hiramatsu et al. | Nov 2009 | A1 |
20090292354 | Gontijo et al. | Nov 2009 | A1 |
20090295295 | Shannon et al. | Dec 2009 | A1 |
20090303465 | Clements et al. | Dec 2009 | A1 |
20090323020 | Zhao et al. | Dec 2009 | A1 |
20100016961 | Hong et al. | Jan 2010 | A1 |
20100016965 | Hong et al. | Jan 2010 | A1 |
20100082017 | Zickler et al. | Apr 2010 | A1 |
20100097569 | Weeber et al. | Apr 2010 | A1 |
20100130888 | Deacon et al. | May 2010 | A1 |
20100161048 | Schaper, Jr. | Jun 2010 | A1 |
20100179793 | Chernyak et al. | Jul 2010 | A1 |
20100220185 | Vertoprakhov et al. | Sep 2010 | A1 |
20100234833 | Dai | Sep 2010 | A1 |
20100315589 | Portney | Dec 2010 | A1 |
20110080562 | Iizuka et al. | Apr 2011 | A1 |
20110149236 | Weeber | Jun 2011 | A1 |
20110166652 | Bogaert et al. | Jul 2011 | A1 |
20110205486 | Zhao | Aug 2011 | A1 |
20110211163 | Meuse et al. | Sep 2011 | A1 |
20120140166 | Zhao | Jun 2012 | A1 |
20120238904 | Manns et al. | Sep 2012 | A1 |
20120249955 | Sarver et al. | Oct 2012 | A1 |
20120310337 | Hacker et al. | Dec 2012 | A1 |
20130050637 | Roffman et al. | Feb 2013 | A1 |
20130226294 | Van Der Mooren et al. | Aug 2013 | A1 |
20130307965 | Widman et al. | Nov 2013 | A1 |
20130314669 | Levin et al. | Nov 2013 | A1 |
20130345807 | Olsen et al. | Dec 2013 | A1 |
20140016088 | De Rossi et al. | Jan 2014 | A1 |
20140135919 | Gontijo et al. | May 2014 | A1 |
20140160436 | Kasthurirangan et al. | Jun 2014 | A1 |
20140176904 | Lai | Jun 2014 | A1 |
20140268042 | Bor et al. | Sep 2014 | A1 |
20140293426 | Dobschal | Oct 2014 | A1 |
20140320805 | Wilzbach et al. | Oct 2014 | A1 |
20150062529 | Kasthurirangan et al. | Mar 2015 | A1 |
20150138350 | Videcoq | May 2015 | A1 |
20150250583 | Rosen et al. | Sep 2015 | A1 |
20150320547 | Rosen et al. | Nov 2015 | A1 |
20150359625 | Argal et al. | Dec 2015 | A1 |
20150362746 | Skudder et al. | Dec 2015 | A1 |
20150379348 | Whritenor et al. | Dec 2015 | A1 |
20160157997 | Gerlach et al. | Jun 2016 | A1 |
20160161364 | Alarcon Heredia | Jun 2016 | A1 |
20160299355 | Biemold et al. | Oct 2016 | A1 |
20160335474 | Santos-Villalobos et al. | Nov 2016 | A1 |
20170189233 | Dewey et al. | Jul 2017 | A1 |
Number | Date | Country |
---|---|---|
3107675 | Jul 1981 | DE |
3439551 | Apr 1986 | DE |
102005022683 | Nov 2006 | DE |
226400 | Jun 1987 | EP |
227357 | Jul 1987 | EP |
3343067 | Nov 1989 | EP |
D457553 | Nov 1991 | EP |
681198 | Nov 1995 | EP |
0538126 | Sep 1996 | EP |
D810427 | Dec 1997 | EP |
3926531 | Jun 1999 | EP |
949529 | Oct 1999 | EP |
957331 | Nov 1999 | EP |
1424049 | Jun 2004 | EP |
1857077 | Nov 2007 | EP |
1310267 | Jan 2008 | EP |
1424049 | Jun 2009 | EP |
2631891 | Aug 2013 | EP |
2653095 | Oct 2013 | EP |
3059575 | Aug 2016 | EP |
2745711 | Sep 1997 | FR |
2433782 | Jul 2007 | GB |
2488802 | Sep 2012 | GB |
2010200915 | Sep 2010 | JP |
8603961 | Jul 1986 | WO |
9222264 | Dec 1992 | WO |
9303409 | Feb 1993 | WO |
9507487 | Mar 1995 | WO |
9856315 | Dec 1998 | WO |
9905499 | Feb 1999 | WO |
0019906 | Apr 2000 | WO |
0111418 | Feb 2001 | WO |
0135868 | May 2001 | WO |
0154569 | Aug 2001 | WO |
0163344 | Aug 2001 | WO |
0182839 | Nov 2001 | WO |
0185016 | Nov 2001 | WO |
0189424 | Nov 2001 | WO |
0221194 | Mar 2002 | WO |
02074210 | Sep 2002 | WO |
03009053 | Jan 2003 | WO |
04028356 | Apr 2004 | WO |
2004034129 | Apr 2004 | WO |
2004053568 | Jun 2004 | WO |
2004079637 | Sep 2004 | WO |
2004090611 | Oct 2004 | WO |
2004096014 | Nov 2004 | WO |
05019906 | Mar 2005 | WO |
2005079546 | Sep 2005 | WO |
06025726 | Mar 2006 | WO |
2006032263 | Mar 2006 | WO |
2006047698 | May 2006 | WO |
06060477 | Jun 2006 | WO |
2006060480 | Jun 2006 | WO |
2007067872 | Jun 2007 | WO |
2007092948 | Aug 2007 | WO |
2007133384 | Nov 2007 | WO |
2007142981 | Dec 2007 | WO |
2008045847 | Apr 2008 | WO |
2008083283 | Jul 2008 | WO |
2009020963 | Feb 2009 | WO |
2009029515 | Mar 2009 | WO |
2009076670 | Jun 2009 | WO |
2009105567 | Aug 2009 | WO |
2009137491 | Nov 2009 | WO |
2010009254 | Jan 2010 | WO |
2010009257 | Jan 2010 | WO |
2010028654 | Mar 2010 | WO |
2012052585 | Apr 2012 | WO |
2012074742 | Jun 2012 | WO |
2012083143 | Jun 2012 | WO |
2012085917 | Jun 2012 | WO |
2012154597 | Nov 2012 | WO |
2012166797 | Dec 2012 | WO |
2015022215 | Feb 2015 | WO |
2016032397 | Mar 2016 | WO |
2016087914 | Jun 2016 | WO |
2016123167 | Aug 2016 | WO |
Entry |
---|
International Search Report and Written Opinion for Application No. PCT/EP2018/082950, dated Mar. 19, 2019, 12 pages. |
Morlock, R., et al., “Patient-Reported Spectacle Independence Questionnaire (PRSIQ): Development and Validation,” American Journal of Ophthalmology, Jun. 2017, vol. 178, pp. 101-114. |
Rosen R.,et al., “A Bayesian Method Using through Focus Visual Acuity to Predict Rates of Spectacle Wear for Pseudophakic patients,” Investigative Ophthalmology & Visual Science, Jul. 2018, vol. 59 (9), pp. 1075, ARVO Annual Meeting Abstract, Retrieved from the Internet: (URL: https://iovs.arvojournals.org/article.aspx?articleid=2693341&resultClick=1). |
Abelman H., et al. “Tolerance and Nature of Residual Refraction in Symmetric Power Space as Principal Lens Powers and Meridians Change,” Computational and Mathematical Methods in Medicine, Article ID 492383, 2014, vol. 2014, pp. 1-12,. |
Alfonso J.F., et al., “Prospective Study of the Acri.LISA Bifocal Intraocular Lens,” Journal of Cataract Refractive Surgery, Nov. 2007, vol. 33 (11), pp. 1930-1935. |
Alio J.L., et al., “Phakic Anterior Chamber Lenses for the Correction of Myopia: A 7-Year Cumulative Analysis of Complications in 263 Cases,” Ophthalmology, Mar. 1999, vol. 106 (3), pp. 458-466. |
Apple D.J., et al., “Anterior Chamber Lenses Part 1: Complications and Pathology and a Review of Designs,” Journal of Cataract Refractive Surgery, Mar. 1987, vol. 13 (2), pp. 157-174. |
Apple D.J., et al., Eds., “Intraocular Lenses: Evolution, Designs, Complications and Pathology,” in: New Concepts in Intraocular Lens Implantation, Williams & Wilkins publisher, Jan. 1989, vol. 22 (36), pp. 205-221. |
Apple D.J., et al., Eds., “Intraocular Lenses: Evolution, Designs, Complications and Pathology,” in: New Concepts in Intraocular Lens Implantation, Williams & Wilkins publisher, Jan. 1989, vol. 36 (1), pp. 21-36. |
Baikoff G., et al., “Angle-fixated Anterior Chamber Phakic Intraocular Lens for Myopia 7 to -19 Diopters,” Journal of Refractive Surgery, May-Jun. 1998, vol. 14 (3), pp. 282-292. |
Baumeister M., et al., “Tilt and Decentration of Spherical and Aspheric Intraocular Lenses: Effect on Higher-Order Aberrations,” Journal of Cataract & Refractive Surgery, 2009, vol. 35 (6), pp. 1006-1012. |
Brainard D.H., The Psychophysics Toolbox, Spatial Vision, vol. 10, pp. 433-436. |
Brown W.L., “Revisions to Tolerances in Cylinder Axis and in Progressive Addition Lens Power in ANSI Z80.1-2005,” Optometry, 2006, vol. 77 (7), pp. 343-349. |
Canovas C., et al., “Customized Eye Models for Determining Optimized Intraocular Lenses Power,” Biomedical Optics Express, Jun. 1, 2011, vol. 2 (6), pp. 1649-1662. |
Canovas C., et al., “Hybrid Adaptive-Optics Visual Simulator,” Optical Letters, Jan. 15, 2010, vol. 35 (2), pp. 196-198. |
Cheng X., et al., “Predicting Subjective Judgment of Best Focus with Objective Image Quality Metrics,” Journal of Vision, Apr. 2004, vol. 4 (4), pp. 310-321. |
CILCO Advertisement Brochure, Oct. 1982, 3 pages. |
Cohen A.L., “Practical Design of a Bifocal Hologram Contact Lens or Intraocular Lens,” Applied Optics, Jul. 1, 1992, vol. 31 (19), pp. 3750-3754. |
De Almeida M.S., et al., “Different Schematic Eyes and their Accuracy to the in Vivo Eye: A Quantitative Comparison Study,” Brazilian Journal of Physics, Jun. 2007, vol. 37 (2A), 10 pages. |
Diffractive Lenses for Extended Depth of Focus and Presbyopic Correction, Presentation from Wavefront Congress held on Feb. 15, 2008, Rochester, New York. |
Doskolovich L.L., et al., “Special Diffractive Lenses,” Lens and Optical Systems Design, Apr. 1992, vol. 1780, pp. 393-402. |
Einighammer H.J., “The Individual Virtual Eye”, Dissertation, 2008, 157 pages. |
Gobbi P.G., et al., “Far and Near Visual Acuity with Multifocal Intraocular Lenses in an Optomechanical Eye Model with Imaging Capability,” Journal of Cataract and Refractive Surgery, 2007, vol. 33 (6), pp. 1082-1094. |
Gobbi P.G., et al., “Optomechanical Eye Model with Imaging Capabilities for Objective Evaluation of Intraocular Lenses,” Journal of Cataract and Refractive Surgery, 2006, vol. 32 (4), pp. 643-651. |
Hill W., et al., “Monte Carlo Simulation of Expected Outcomes with the Acrysof Toric Intraocular Lens,” BMC Ophthalmology, Oct. 2008, vol. 8, pp. 22. |
Kim J.H., et al., “The Analysis of Predicted Capsular Bag Diameter using Modified Model of Capsule Measuring Ring in Asians,” Clinical and Experimental Ophthalmology, Apr. 2008, vol. 36 (3), pp. 238-244. |
Kim M.J., et al., “Objective Evaluation of Through-Focus Optical Performance of Presbyopia-Correcting Intraocular Lenses Using an Optical Bench System,” Journal of Cataract and Refractive Surgery, 2011, vol. 37 (7), pp. 1305-1312. |
Klein S.A., “Optimal Corneal Ablation for Eyes with Arbitrary Hartmann-Shack Aberrations,” Journal of the Optical Society of America A, 1998, vol. 15 (9), pp. 2580-2588. |
Liang J., et al, “Objective Measurement Of Wave Aberrations Of The Human Eye With The Use Of A Hartmann-Shack Wave-Front Sensor,” Journal of the Optical Society of America, 1994, vol. 11 (7), pp. 1949-1957. |
Liou H.L., et al., “Anatomically Accurate, Finite Model Eye for Optical Modeling,” Journal of Optical Society of America, Aug. 1997, vol. 14 (8), pp. 1684-1695. |
Liou H.L., et al., “The Prediction of Spherical Aberration with Schematic Eyes,” Ophthalmic and Physiological Optics, Jan. 1996, vol. 16 (4), pp. 348-354. |
Marinho A., “Results are Encouraging for Phakic IOLs, but More Work is needed,” Refractive Surgery, Feb. 2000, p. 12, 15. |
Marsack J.D., et al., “Metrics of Optical Quality Derived from Wave Aberrations Predict Visual Performance,” Journal of Vision, Apr. 2004, vol. 4 (4), pp. 322-328. |
Menapace R., “The Capsular Tension Rings,” Journal of Cataract & Refractive Surgery, Dec. 10, 2008, Chap. 3, pp. 27-44. |
Mencucci R., et al., “Clinical outcomes and rotational stability of a 4-haptic toric intraocular lens in myopic eyes,” Journal of Cataract & Refractive Surgery, Sep. 2014, vol. 40 (9), pp. 1479-1487. |
Monsoriu J.A., et al., “Devil's Lenses,” Optics Express, Oct. 17, 2007, vol. 15 (21), pp. 13858-13864. |
Navarro R., et al., “Accommodation-Dependent Model of the Human Eye with Aspherics,” Journal of the Optical Society of America, Aug. 1985, vol. 2 (8), pp. 1273-1281. |
Nio Y.K., et al., “Effect of Intraocular Lens Implantation on Visual Acuity, Contrast Sensitivity, and Depth of Focus,” Journal of Cataract and Refractive Surgery, Nov. 2003, vol. 29 (11), pp. 2073-2081. |
Norrby S., et al., “Model Eyes for Evaluation of Intraocular Lenses,” Applied Optics, Sep. 7, 2007, vol. 46 (26), pp. 6595-6605. |
Olsen T., “Simple Method to Calculate the Surgically Induced Refractive Change,” Journal of Cataract & Refractive Surgery, Mar. 1993, vol. 19 (2), pp. 319-320. |
Peli E., et al., “Appearance of Images Through A Multifocal Intraocular Lens,” Journal of the Optical Society of America, 2001, vol. 18 (2), pp. 302-309. |
Piers P.A., et al., “Eye Models for the Prediction of Contrast Vision in Patients with New Intraocular Lens Designs,” Optics Letters, Apr. 1, 2004, vol. 29 (7), pp. 733-735. |
Piers P.A., et al., “Theoretical Comparison of Aberration-Correcting Customized and Aspheric Intraocular Lenses,” Journal of Refractive Surgery, Apr. 2007, vol. 23 (4), pp. 374-384. |
Praeger D.L., “Praeger Technique for the Insertion of the Copeland Radial IOL Posterior Chamber Placement,” Copeland Lens, 1982, 7 pages. |
Siedlecki D., et al., “Radial Gradient index Intraocular Lens: a Theoretical Model,” Journal of Modern Optics, Feb. 20-Mar. 10, 2008, vol. 55 (4-5), pp. 639-647. |
Strenn K., et al., “Capsular bag Shrinkage after Implantation of an Open-Loop Silicone Lens and a Poly(methyl methacrylate) Capsule Tension Ring,” Journal of Cataract and Refractive Surgery, Dec. 1997, vol. 23 (10), pp. 1543-1547. |
Tehrani M., et al., “Capsule Measuring Ring to Predict Capsular Bag Diameter and Follow its Course after Foldable Intraocular Lens Implantation,” Journal of Cataract Refractive Surgery, Nov. 2003, vol. 29 (11), pp. 2127-2134. |
Terwee T., et al., “Visualization of the Retinal Image in an Eye Model With Spherical and Aspheric, Diffractive, and Refractive Multifocal Intraocular Lenses,” Journal of Refractive Surgery, Mar. 2008, vol. 24 (3), pp. 223-232. |
Van Den Berg T.J., “Analysis of Intraocular Straylight, Especially in Relation to Age,” Optometry and Vision Science, Feb. 1995, vol. 72 (2), pp. 52-59. |
Van Meeteren A., “Calculations on the Optical Modulation Transfer Function of the Human Eye for White Light,” Optica Acta, May 1974, vol. 21 (5), pp. 395-412. |
Vass C., et al., “Prediction of Pseudophakic Capsular bag Diameter based on Biometric Variables,” Journal of Cataract and Refractive Surgery, Oct. 1999, vol. 25 (10), pp. 1376-1381. |
Villegas E.A., et al., “Correlation between Optical and Psychophy, Sical Parameters as a Function of Defocus,” Optometry and Vision Science, Jan. 1, 2002, vol. 79 (1), pp. 60-67. |
Abrahamsson M., et al., “Impairment of Contrast Sensitivity Function (CSF) as a Measure of Disability Glare,” Investigative Ophthalmology & Visual Science, Jul. 1986, vol. 27 (7), pp. 1131-1136. |
Aslam, T.M., et al., “Development of a Forced Choice Photographic Questionnaire For Photic Phenomena and Its Testing—Repeatability, Reliability and Validity,” Ophthalmologica, Nov.-Dec. 2004, vol. 218 (6), pp. 402-410. |
Beer J.M., et al., “Lasers' Spectral and Temporal Profile Can Affect Visual Glare Disability,” Aviation, Space, and Environmental Medicine, Dec. 2012, vol. 83 (12), pp. 1135-1144. |
Calatayud A., et al., “Imaging Quality of Multifocal Intraocular Lenses: Automated Assessment Setup,” Ophthalmic and Physiological Optics, Jul. 2013, vol. 33 (4), pp. 420-426. |
Fernandez E.J., et al., “Adaptive Optics Visual Simulator,” Journal of Refractive Surgery, 2002, vol. 18 (5), pp. S634-S638. |
Guirao A., et al., “Corneal Wave Aberration from Videokeratography: Accuracy And Limitations of the Procedure,” Journal of the Optical Society of America, 2000, vol. 17 (6), pp. 955-965. |
Jaeken B., et al., “Peripheral Aberrations in the Human Eye for Different Wavelengths: Off-Axis Chromatic Aberration,” Journal of the Optical Society of America A, Sep. 2011, vol. 28 (9), pp. 1871-1879. |
Javitt J.C., et al., “Validity and Reliability of the Cataract TyPE Spec: an Instrument For Measuring Outcomes of Cataract Extraction,” American Journal of Ophthalmology, Aug. 2003, vol. 136 (2), pp. 285-290. |
Jendritza B.B., et al., “Wavefront-Guided Excimer Laser Vision Correction after Multifocal IOL Implantation,” Journal of Refractive Surgery, Mar. 2008, vol. 24 (3), pp. 274-279. |
Johnson C.A., “Psychophysical Factors that Have Been Applied to Clinical Perimetry,” Vision Research, Sep. 2013, vol. 90, pp. 25-31. |
Lesmes L.A., et al., “Bayesian Adaptive Estimation of the Contrast Sensitivity Function: the Quick CSF Method,” Journal of Vision, Mar. 2010, vol. 10 (3) 17, pp. 1-21. |
Ortiz, C., et al., “Quantification and Monitoring of Visual Disturbances for patients with cataracts using Halo v1.0 software,” Department of Optics, Laboratory of Vision Sciences and Applications, University of Granada, IWBBIO 2013, Mar. 20, 2013, XP055596332, Proceedings, 8 Pages. |
Vitale S., et al., “The Refractive Status and Vision Profile: A Questionnaire to Measure Vision-Related Quality of Life in Persons with Refractive Error,” Ophthalmology, Aug. 2000, vol. 107 (8), pp. 1529-1539. |
Weeber H.A., et al., “Influence of Corneal Aberrations on Dysphotopsia with Multifocal IOLs,” Arvo, 2011, Abstract. |
Weeber H.A., et al., “Influence of Corneal Aberrations on Dysphotopsia with Multifocal IOLs,” RD3115, 2011. |
Weeber H.A., et al., “Optical and Visual Performance of Patient Populations Implanted with Monofocal and Multifocal IOLs in the Presence of Defocus,” Investigative Ophthalmology & Visual Science, 2010, vol. 51, E-Abstract 5751. |
Weeber H.A., et al., “Population-based Visual Acuity in the Presence of Defocus Well Predicted By Classical Theory,” Journal of Biomedical Optics, 2010, vol. 15 (4), pp. 040509. |
Weeber H.A., et al., “Theoretical Performance of Intraocular Lenses Correcting Both Spherical and Chromatic Aberration,” Journal of Refractive Surgery, 2012, vol. 28 (1), pp. 48-52. |
Number | Date | Country | |
---|---|---|---|
20190164647 A1 | May 2019 | US |
Number | Date | Country | |
---|---|---|---|
62593162 | Nov 2017 | US |